The FY2025 (Dec) proxy of Keros Therapeutics names 19 peer companies for pay. Among Keros Therapeutics and these peers, CEO pay was the lowest of 8 and total shareholder return was 7th highest of 8.
8th highest of 8in Keros Therapeutics and its pay peers, FY2025 (Dec) by CEO pay:
$2.5M$33.3M
7th highest of 8in Keros Therapeutics and its pay peers, FY2025 (Dec) by total shareholder return:
$20$487
Pay peer group, FY2025 (Dec) proxy
| Scholar Rock Holding | ||
| Protagonist Therapeutics | ||
| Disc Medicine | ||
| IDEAYA Biosciences | ||
| Celldex Therapeutics | ||
| Kura Oncology | ||
| Relay Therapeutics | ||
| Akero Therapeutics, Inc. | Not disclosed | Not disclosed |
| Arcturus Therapeutics Holdings | Not disclosed | Not disclosed |
| Crinetics Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Geron | Not disclosed | Not disclosed |
| Iovance Biotherapeutics | Not disclosed | Not disclosed |
| KalVista Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Longboard Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Pliant Therapeutics, Inc. | Not disclosed | Not disclosed |
| Replimune Group, Inc. | Not disclosed | Not disclosed |
| Rocket Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| SpringWorks Therapeutics, Inc. | Not disclosed | Not disclosed |
| Syndax Pharmaceuticals | Not disclosed | Not disclosed |
'%20fill='%23224a7c'/%3e%3c/clipPath%3e%3cclipPath%20id='clip-path-2'%3e%3cpath%20id='Path_4394'%20d='M4.892,12.4c.758.192,1.629.412,2.67.6a27,27,0,0,0,5.02.426,18.387,18.387,0,0,0,4.07-.6,15.613,15.613,0,0,1,3.2-.6,2.179,2.179,0,0,1,1.861.814,3.668,3.668,0,0,1,.542,1.724c.058.524.058.872.35,1.086a3.609,3.609,0,0,0,1.821.31c.95.02,2.268-.02,3.12-.058s1.24-.077,1.531.1a1.153,1.153,0,0,1,.485.989,10.163,10.163,0,0,0-.136,1.3,2.4,2.4,0,0,0,.717,1.142,4.087,4.087,0,0,1,.872,1.222.844.844,0,0,1-.446,1.066,5.765,5.765,0,0,1-2.171.5,10.913,10.913,0,0,0-2.326.271c-.465.194-.426.581-.155.988s.776.833,1.028,1.3a1.084,1.084,0,0,1-.136,1.357,4.056,4.056,0,0,1-1.977.814c-.814.155-1.667.194-2.442.329a12.864,12.864,0,0,0-1.978.543c-.5.175-.814.291-.969.621a.85.85,0,0,0,.427,1.163,13.866,13.866,0,0,0,2.616.5c.872.175,1.453.484,1.55,1.047a13.544,13.544,0,0,1-.368,2.229,3.628,3.628,0,0,0,.523,2.267,1.967,1.967,0,0,0,1.589.755,8,8,0,0,0,2.364-.077,8.558,8.558,0,0,0,1.822-.736,1.836,1.836,0,0,1,1.861-.1,4.294,4.294,0,0,1,1.182,2.326c.194.872.155,1.569.891,2.015a14.815,14.815,0,0,0,3.664.93A14,14,0,0,1,41.4,42.242a9.687,9.687,0,0,1,1.736,1.229A24.91,24.91,0,1,0,4.892,12.4'%20transform='translate(-4.892%20-0.176)'%20fill='%23224a7c'/%3e%3c/clipPath%3e%3c/defs%3e%3cg%20id='Group_3541'%20transform='translate(-0.094%20-0.128)'%3e%3cg%20id='Group_3282'%20transform='translate(0.094%2015.73)'%3e%3cg%20id='Group_3281'%20clip-path='url(%23clip-path)'%3e%3crect%20id='Rectangle_2848'%20width='33.837'%20height='20.982'%20transform='translate(-0.094%2033.75)%20rotate(-89.841)'%20fill='%23224a7c'/%3e%3c/g%3e%3c/g%3e%3cg%20id='Group_3284'%20transform='translate(3.563%200.128)'%3e%3cg%20id='Group_3283'%20clip-path='url(%23clip-path-2)'%3e%3crect%20id='Rectangle_2849'%20width='43.423'%20height='46.468'%20transform='translate(-0.12%2043.294)%20rotate(-89.841)'%20fill='%23224a7c'/%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23FEFEFE'%3e%3cpath%20d='M67.7444739,25%20L33.1043073,38.2478027%20L34.7958615,41.1131448%20L41.0490807,51.7151219%20L29.0986607,51.7151219%20L28,54.6065381%20L57.1428867,79%20L60.0675871,77.3612019%20L46.8800441,55.0029363%20L63.0277166,55.0032886%20L63.8216155,51.7151219%20L70,26.9178624%20L67.7444739,25%20Z%20M38,39.9222264%20L66,29%20L60.3908123,52%20L44.9725093,52%20L38,39.9222264%20Z%20M34,55%20L43.1090246,55%20L52,70%20L34,55%20Z'%20id='Fill-1-Copy'/%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
19 companies
Changes by year
FY2025 (Dec) proxy
- AddedCelldex Therapeuticspay peer group
- AddedDisc Medicinepay peer group
- AddedLongboard Pharmaceuticals, Inc.pay peer group
- AddedPliant Therapeutics, Inc.pay peer group
- AddedRelay Therapeuticspay peer group
- RemovedEditas Medicine, Inc.pay peer groupbecause they were well below the market capitalization parameters described above
- RemovedMersana Therapeutics, Inc.pay peer groupbecause they were well below the market capitalization parameters described above
- RemovedMorphic Holding Inc.pay peer groupRemoved Morphic Holding Inc., as it was acquired in August 2024
- RemovedZentalis Pharmaceuticals, Inc.pay peer groupbecause they were well below the market capitalization parameters described above
FY2024 (Dec) proxy
- AddedMorphic Holding, Inc.pay peer group
- AddedProtagonist Therapeuticspay peer group
- RemovedFulcrum Therapeuticspay peer groupbecause they were well below the market capitalization parameters described above
- RemovedKezar Life Sciences, Inc.pay peer groupbecause they were well below the market capitalization parameters described above
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.